WALTHAM, Mass., June 3 /PRNewswire-FirstCall/ -- Interleukin Genetics,
Inc. (Amex: ILI), announced today that Dr. Kenneth Kornman, Chief
Scientific Officer, will present at the 13th International Conference on
Periodontal Research (ICPR) on June 6, 2008 in Ljubljana, Slovenia on the
genetic and environmental factors that control inflammation differences
among individuals. The ICPR meeting has been held approximately every three
years since 1969 to bring together the world's leaders in periodontal
research to reassess the current knowledge in the field and to identify new
research direction, to improve the diagnosis, prevention, and treatment of
periodontal diseases.

Periodontitis is a bacterially-induced chronic inflammatory disease
that causes destruction of bone and other tissues that support the teeth.
Severe periodontitis, that usually leads to loss of multiple teeth, is
found in approximately 8-13 percent of the adult population. The presence
and severity of periodontitis have been associated with an increased risk
for other important inflammatory conditions, including pre-term births,
cardiovascular disease, rheumatoid arthritis, and certain cancers.

WHO: Dr. Kenneth Kornman, Chief Scientific Officer of Interleukin

Genetics

WHERE: 13th International Conference on Periodontal Research (ICPR) in

Ljubljana, Slovenia

WHEN: Friday, June 6, 2008 at 9:45-10:30 GMT

WHAT: Approximately 30-60 percent of the severity of periodontal disease

is determined by genetics. Interleukin Genetics developed and

markets the PST(R) genetic test to help identify individuals at

increased risk for severe periodontal disease and complications

from dental implants. This test helps dentists guide the

management of their patients' periodontal disease to avoid

complications of severe periodontitis.

About Interleukin Genetics

Interleukin Genetics, Inc. (Amex: ILI) is a genetics-focused
personalized health company that develops preventive consumer products and
genetic tests for sale to the emerging personalized health market. Focused
on the future of health and medicine, Interleukin uses its leading genetics
research and scientific capabilities to develop and test innovative
preventive and therapeutic products. Interleukin is headquartered in
Waltham, MA. For more information about Interleukin, its products and
ongoing programs, please visit http://www.ilgenetics.com.

Certain statements contained herein are "forward-looking" statements
including statements regarding our ability to develop diagnostic,
personalized nutritional and therapeutic products to prevent or treat
diseases of inflammation and other genetic variations, our ability to
screen nutritional compounds for their effects on inflammatory responses
and other genetic variations, given specific genetic patterns and our
ability to make progress in advancing our core technologies. Because such
statements include risks and uncertainties, actual results may differ
materially from those expressed or implied by such forward-looking
statements. Factors that could cause actual results to differ materially
from those expressed or implied by such forward-looking statements include,
but are not limited to, the risk of market acceptance of our products, the
risk of technology and product obsolescence, delays in product development,
the performance of our commercial partners, the availability of adequate
capital, the actions of our competitors and other competitive risks, and
those risks and uncertainties described in our annual reports on Form 10-K,
our quarterly reports on Form 10-Q and other documents we file with, or
furnish to, the Securities and Exchange Commission. We disclaim any
obligation or intention to update these forward-looking statements.

(Date:10/11/2017)... ... ... Personal eye wash is a basic first aid supply for any work environment, but most ... you rinse first if a dangerous substance enters both eyes? It’s one less decision, and ... unique dual eye piece. , “Whether its dirt and debris, or an acid or alkali, ...

(Date:10/11/2017)... LAGUNA HILLS, Calif. , Oct. 11, 2017 ... London (ICR) and University of ... prognostic tool to risk-stratify patients with multiple myeloma (MM), in ... nine . The University of Leeds ... by Myeloma UK, and ICR will perform the testing services ...

(Date:10/10/2017)... ... 10, 2017 , ... San Diego-based team building and cooking events company, Lajollacooks4u, ... The bold new look is part of a transformation to increase awareness, appeal ... growth period. , It will also expand its service offering from its signature gourmet ...

(Date:10/10/2017)... , Oct. 10, 2017 International research firm Parks ... Strategy, will speak at the TMA 2017 Annual Meeting , October ... trends in the residential home security market and how smart safety and ... Parks ... "The residential ...

(Date:6/14/2017)... IBM ) is introducing several innovative partner startups at VivaTech ... startups and global businesses, taking place in Paris ... will showcase the solutions they have built with IBM Watson ... France is one of the most dynamic ... in the number of startups created between 2012 and 2015*, ...

(Date:5/6/2017)... -- RAM Group , Singaporean based technology ... biometric authentication based on a novel quantum-state ... perform biometric authentication. These new sensors are based on a ... Group and its partners. This sensor will have widespread ... security. Ram Group is a next generation sensor ...